Back to top
more

Cencora, Inc. (COR)

(Delayed Data from NYSE)

$283.78 USD

283.78
2,379,369

-8.57 (-2.93%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $283.62 -0.16 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (73 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Compared to Estimates, Cencora (COR) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Cencora (COR) Q3 Earnings Beat Estimates, '24 View Raised

by Zacks Equity Research

Cencora's (COR) third-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Zacks Equity Research

Cencora (COR) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Cencora (COR) delivered earnings and revenue surprises of 5.03% and 0.90%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

Will These 4 MedTech Stocks Beat Forecasts This Earnings Season?

by Indrajit Bandyopadhyay

Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, XRAY, GEHC and GKOS are placed ahead of their earnings release.

Zacks Equity Research

Can Cigna (CI) Beat Q2 Earnings on Growing Pharmacy Revenues?

by Zacks Equity Research

Cigna's (CI) second-quarter earnings are expected to benefit from rising premiums and pharmacy revenues, partially offset by rising expenses.

Zacks Equity Research

Why Cencora (COR) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Here's Why Cencora (COR) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Countdown to Cencora (COR) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Evaluate the expected performance of Cencora (COR) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Equity Research

Cencora (COR) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

Cencora's (COR) third-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.

Zacks Equity Research

Natera (NTRA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Natera (NTRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Do Options Traders Know Something About Cencora (COR) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Cencora (COR) stock based on the movements in the options market lately.

Zacks Equity Research

Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Strength Seen in Embecta Corp. (EMBC): Can Its 6.9% Jump Turn into More Strength?

by Zacks Equity Research

Embecta Corp. (EMBC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Backlog Conversion Likely to Aid Medpace's (MEDP) Q2 Earnings

by Zacks Equity Research

Continued strength in backlog conversion rate is likely to have boosted Medpace's (MEDP) top line in the second quarter.

Zacks Equity Research

Will High Medical Care Costs Hurt Molina's (MOH) Q2 Earnings?

by Zacks Equity Research

Molina's (MOH) second-quarter performance is likely to have been affected by high medical care costs, partly offset by rising membership in all three businesses.

Zacks Equity Research

Can HCA Healthcare (HCA) Beat Q2 Earnings on Growing Admissions?

by Zacks Equity Research

HCA Healthcare's (HCA) second-quarter earnings are likely to benefit from improved admissions and payer mix, partially offset by rising operating expenses.

Zacks Equity Research

AngioDynamics (ANGO) Q4 Earnings Top Estimates, Gross Margin Down

by Zacks Equity Research

AngioDynamics (ANGO) registers overall strong top-line results on a pro-forma basis in fourth-quarter fiscal 2024, driven by strength in the Med Tech business.

Zacks Equity Research

Can Elevance Health (ELV) Beat Q2 Earnings on Lower Expenses?

by Zacks Equity Research

Elevance Health's (ELV) second-quarter results are likely to be aided by improved product revenues, commercial fee-based membership growth, and lower expenses.

Zacks Equity Research

Why Cencora (COR) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Why Cencora (COR) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Cencora (COR) Stock Nosedives: Here's What Caused the Decline

by Zacks Equity Research

Cencora (COR) shares declined on Jun 27, following an unfavorable ruling from the Supreme Court related to a previously settled litigation. Here we discuss the key factors that likely led to the decline.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now

by Zacks Equity Research

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zacks Equity Research

Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for ONEV

Zacks Equity Research

Cencora (COR) Gains 13.2% YTD: What's Driving the Stock?

by Zacks Equity Research

Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.